Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment

This study expands and validates the pilot study NCT06381284. It is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The primary objective is to determine the validity of a self-assessment tool in encouraging undiagnosed participants, recruited through a social media campaign, to seek medical evaluation for suspected myasthenia gravis (MG).

NCT Number	NCT06866483
Lead Sponsor	ZS Associates Collaborators: UCB Pharma, University of California, San Francisco
Conditions	Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
Enrollment	1,000 participants
Start Date	2025-02-26
Primary Completion	2025-12-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-03-10